Genmab AS

Genmab AS P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Genmab AS (GMAB) as of Nov 22, 2026 is 13.39. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 2.03 — a change of 559.53% (higher).

P/FCF

13.39

YoY

559.53%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Genmab AS is 2025 13.39 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Genmab AS was 2024 2.03 . It decreases by 559.53% higher compared to the previous year.

The Genmab AS P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
28.65 USD
Jan 1, 2019
12.67 USD
Jan 1, 2020
2.51 USD
Jan 1, 2021
7.79 USD
Jan 1, 2022
4.28 USD
Jan 1, 2023
2.20 USD
Jan 1, 2024
2.03 USD
Jan 1, 2025
13.39 USD
The Genmab AS P/FCF history
YEARP/FCFYoY
13.39+559.53%
2.03-7.65%
2.20-48.67%
4.28-45.03%
7.79+210.02%
2.51-80.17%
12.67-55.77%
28.65+179.20%
10.26-80.37%
52.26-40.24%
87.46-67.49%
269.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Genmab AS is 13.39 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Genmab AS changed from 2.03 to 13.39, representing a 559.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Genmab AS since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Genmab AS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genmab AS

All Key Metrics — Genmab AS